Phase 1 Dose Escalation Study for VIP943 Subjects With Advanced CD123+ Hematologic Malignancies
Conditions: Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia; High-risk Myelodysplastic Syndrome Intervention: Drug: VIP943 Sponsor: Vincerx Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials